Menu

Federal Science Funding Could Increase Under New Budget Deal

Congress has increased discretionary spending caps, making it possible that the budgets of US science agencies will rise this fiscal year.

Feb 12, 2018
Shawna Williams

ISTOCK, OPENMINDEDEThe budget deal signed into US law on Friday (February 9) increases the caps on nondefense discretionary spending—a category that includes science agencies such as the National Institutes of Health, the National Science Foundation, and NASA—by $143 billion (12.9 percent) in fiscal year 2018, and by $153 billion in 2019, reports the American Association for the Advancement of Science (AAAS). But how those funds will be allocated will not be determined until Congress passes an appropriations bill.

AAAS’s Matt Hourihan tells Science News that “Generally, research and development funding tends to track the discretionary budget pretty closely . . . most likely we're looking at a larger increase this year, and then a far more moderate increase next year. Within that context, agencies will fare better or worse based on their current popularity.”

In response to the news about the deal, which ended a very brief government shutdown, the American Chemical Society (ACS) released a statement that reads in part, “ACS is encouraged by the bipartisan budget deal that includes an increase in domestic spending over two years. ACS encourages Congress to invest heavily in scientific research and education, which are key elements of the U.S. innovation pipeline that drives job creation and economic growth.”

Defense spending caps also increased under Friday’s deal. The White House is expected to release a proposed budget today (February 12) that reflects the new funding limits. Such proposals from the president are not binding, but reflect the administration’s priorities, CNBC reports.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.